Remote patient-monitoring company Athelas scored $132 million across two funding rounds, earning the startup unicorn status with a valuation of $1.5 billion.

General Catalyst and Tribe Capital each led one of the financing rounds. Other participants include Sequoia Capital, YCombinator, Greenoaks, Human Capital and Initialized Capital.

Athelas' flagship product, the Athelas One, uses a finger prick to draw blood and share metrics like white blood cell count with providers. It also offers a connected glucometer, blood pressure cuff, scale and medication-tracking device.

"Athelas has been making steady progress in proving the impact that RPM can have in helping providers serve their chronic patients in their homes. Their integrated suite of software, services and devices are being used to serve tens of thousands of patients, and the company is poised to be a leader in this category," Hemant Taneja, managing partner at General Catalyst, said in a statement. Taneja will also serve on the Athelas board. 

League, which offers a platform to assist healthcare organizations and consumer health companies in building digital tools, has raised $95 million in Series C funding.

The round was led by TDM Growth Partners, with participation from Workday Ventures and existing investors. The startup said the round brings its total raise to $205 million.

League said it will use the capital to scale Health OS, its platform-as-a-service product. Its Series B round, raised in 2018, brought in $62 million CAD. 

"With the support of leading platform investors, League’s PaaS offering is positioned as the de facto digital infrastructure to build comprehensive healthcare consumer experiences. Providers, payers, consumer health partners and employers use League’s platform to build unique and differentiated applications that transform healthcare from a patchwork of disparate point solutions to a cohesive experience that just works," the company's CEO and founder Michael Serbinis said in a statement.

Cancer-care-coordination platform Jasper Health scored $25 million in a Series A round led by General Catalyst.

Other participants in the round include Human Capital, W Health Ventures, Redesign Health and 7wireVentures. The startup plans to use the Series A financing to expand its sales and operations teams, improve its platform and invest in research.

"No one experiencing cancer should be crushed by the weight of managing their own treatment, but unfortunately, that's the experience for many people. Jasper Health is on a mission to change that," Adam Pellegrini, cofounder and CEO of Jasper Health, said in a statement. 

"Our team is incredibly proud of the business momentum we've experienced over the last year, and we are driven by the extraordinary stories we hear from our members to continue growing. We've built the platform. We've demonstrated the outcomes. Now it's time to bring Jasper to millions more through partnerships with large enterprises."

Virtual specialty care platform Summus Global announced Tuesday it brought in a $22 million strategic investment from Danaher Corporation's cofounder and executive committee chairman Mitchell Rales and the Glenstone Foundation.

The investment comes less than a year after a $21 million Series B round, and brings the company's total raise to $50 million. It plans to use the funds for growth, including for improving condition-specific patient care journeys.

London-based Zetta Genomics raised £2.5 million ($3.4 million) in seed funding from Nina Capital, APEX Medical and Cambridge Enterprise. 

The University of Cambridge spinout developed the XetaBase platform, which allows researchers to store, access and study genomic and clinical data. Zetta will use the funding to add partnerships as it opens offices in Spain and the U.S. The startup also plans to expand its team.

"Zetta Genomics re-imagines data to deliver a dynamic platform fit for the fast-emerging, fast-scaling, multi-petabyte environment. In liberating genomic data – placing its power into the hands of researchers and clinicians – we will drive precision medicine’s transformation into mainstream healthcare and life-changing patient benefit," Zetta founder Ignacio Medina said in a statement.